Screener
Spyre Therapeutics, Inc. SYRE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by financing activities | 12,255 | 125 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | 11,464 | (40,930) |
| CASH AND CASH EQUIVALENTS | ||
| Beginning of period | 85,721 | 89,423 |
| End of period | $97,185 | $48,493 |
| Supplemental Disclosure of Non-Cash Financing Information: | ||
| Proceeds from stock option exercises received in subsequent period | $987 | — |
| Allocation of deferred offering costs against proceeds of issuance of common stock | $3 | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s cash & equivalents?
- Spyre Therapeutics, Inc. (SYRE) reported cash & equivalents of $97.19M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Spyre Therapeutics, Inc.'s cash & equivalents increased by 100.4% year-over-year, from $48.49M to $97.19M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s cash & equivalents has grown at a -1.0% compound annual growth rate (CAGR), from $90.1M to $85.72M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Spyre Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude